REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2024, after U.S. markets close on Tuesday, May 21, 2024. Alvotech will also conduct a conference call with analysts to present the first quarter 2024 financial results and recent business highlights on Wednesday May 22, 20 ...

REYKJAVIK, Iceland, May 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be participating in the upcoming BofA Securities Healthcare Conference 2024, which will be held on May 14-15, 2024 in Las Vegas, NV. Members of Alvotech's management team will be attending the conference and hosting one-on-one meetings with investors. About Alvotec ...

The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritisAlvotech is the first company to publicly announce positive topline results from a patient study evaluating a biosimilar candidate to Simponi or Simponi Aria REYKJAVIK, Iceland, April 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufa ...

Core Insights - The FDA has approved SELARSDI (ustekinumab-aekn) as a biosimilar to Stelara for treating moderate to severe plaque psoriasis and active psoriatic arthritis in both adults and pediatric patients aged 6 years and older [1][2][10] - SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson [1][3] - The approval of SELARSDI marks the second biosimilar approved under the strategic partnership between Alvotech and Teva, with Teva responsible for its exclusive commercialization in the U.S. [1][4] Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a global leader in the biosimilar space [8] - Teva Pharmaceutical Industries Ltd. is a global pharmaceutical leader with a strong portfolio, leveraging generics expertise and innovation [9] Market Context - Sales of the reference product Stelara in the U.S. were nearly $7 billion in 2023, indicating significant market potential for SELARSDI [3] - The biosimilars market is growing globally and in the U.S., with biosimilars being a key component of Teva's Pivot to Growth strategy [2] Development and Approval Process - The FDA approval of SELARSDI was based on a comprehensive clinical development program, including studies that demonstrated equivalent efficacy and safety compared to Stelara [5][6] - The development utilized a purpose-built end-to-end platform for biosimilars, employing the same cell type and continuous perfusion process as the reference product [2][5] Strategic Partnership - The strategic partnership between Alvotech and Teva was established in August 2020 for the exclusive commercialization of multiple biosimilar candidates, with recent expansions to include additional products [4] - This partnership allows Teva to leverage its extensive sales and marketing infrastructure to bring biosimilars to market effectively [4]

REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a market update at 12:15 pm GMT / 08:15 am EDT on April 3, 2024. Anil Okay, Chief Commercial Officer, will be providing the update. Information on how to access the webcast is posted on Alvotech's investor website at https://investors.alvotech.com/events/even ...

REYKJAVIK, Iceland, March 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO) (the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and thirty thousand (USD 130,000) by issuing thirteen million (13,000,000) ordinary shares. The Company's subsidiary, Alvotech Manco ehf. (the "subsidiary"), has subscribed to all of the newly issued shares for a price of USD ...

Alvotech (NASDAQ:ALVO) Q4 2023 Earnings Conference Call March 21, 2024 8:00 AM ET Company Participants Benedikt Stefansson - Senior Director of Investor Relations & Global Communications Robert Wessman - Chairman & Chief Executive Officer Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Ming Li - Chief Strategy Officer Conference Call Participants Balaji Prasad - Barclays Carl Byrnes - Northland Capital Markets Kirsty Ross Stewart - Citi Thibault Boutherin - Morgan Stanley Patrik ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 20-F ____________________ (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUA ...

EXHIBIT 99.1 Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update Total Revenues in 2023 were $93.4 million, up 10% from previous year Product Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up by 37% from the same period last year Alvotech's Simlandi™ biosimilar to Humira (adalimumab) was approved in the U.S. as the first highconcentration biosimilar with interchangeable status Sales of Alvotech's Jamtek ...

Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up by 37% from the same period last yearAlvotech's Simlandi™ biosimilar to Humira® (adalimumab) was approved in the U.S. as the first high-concentration biosimilar with interchangeable statusSales of Alvotech's Jamteki™ biosimilar to Stelara® (ustekinumab) started in Canada with launches expected in Japan in Q2 and ...